RJA
SAGE icon

Raymond James & Associates’s Sage Therapeutics SAGE Stock Holding History

Raymond James & Associates’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,435
Closed -$632K – 3925
2023
Q2 		$632K Buy
13,435
+3,719
+38% +$185K ﹤0.01% 2780
2023
Q1 		$408K Buy
9,716
+3,411
+54% +$147K ﹤0.01% 3036
2022
Q4 		$240K Buy
+6,305
New +$241K ﹤0.01% 3340
2021
Q2 		– Sell
-9,702
Closed -$726K – 4188
2021
Q1 		$726K Sell
9,702
-3,058
-24% -$251K ﹤0.01% 2728
2020
Q4 		$1.1M Sell
12,760
-83,725
-87% -$6.17M ﹤0.01% 2278
2020
Q3 		$5.9M Buy
96,485
+69,147
+253% +$3.5M 0.01% 1134
2020
Q2 		$1.14M Buy
27,338
+6,397
+31% +$232K ﹤0.01% 2073
2020
Q1 		$601K Buy
20,941
+12,331
+143% +$714K ﹤0.01% 2298
2019
Q4 		$622K Sell
8,610
-26,648
-76% -$3.28M ﹤0.01% 2571
2019
Q3 		$4.95M Sell
35,258
-2,133
-6% -$357K 0.01% 1231
2019
Q2 		$6.85M Buy
37,391
+4,284
+13% +$731K 0.01% 1062
2019
Q1 		$5.27M Buy
33,107
+10,602
+47% +$1.54M 0.01% 1159
2018
Q4 		$2.16M Buy
22,505
+631
+3% +$72.2K ﹤0.01% 1606
2018
Q3 		$3.09M Buy
21,874
+3,341
+18% +$516K ﹤0.01% 1533
2018
Q2 		$2.9M Buy
18,533
+4,304
+30% +$676K ﹤0.01% 1535
2018
Q1 		$2.29M Sell
14,229
-352
-2% -$59.8K ﹤0.01% 1620
2017
Q4 		$2.4M Buy
14,581
+414
+3% +$40.1K ﹤0.01% 1575
2017
Q3 		$883K Sell
14,167
-8,631
-38% -$678K ﹤0.01% 2174
2017
Q2 		$1.82M Buy
22,798
+8,561
+60% +$619K ﹤0.01% 1629
2017
Q1 		$1.01M Sell
14,237
-10,218
-42% -$599K ﹤0.01% 1973
2016
Q4 		$1.25M Buy
24,455
+17,051
+230% +$804K ﹤0.01% 1806
2016
Q3 		$341K Buy
+7,404
New +$301K ﹤0.01% 2537

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James & Associates's SAGE Position: Q3 2023 in Review

Raymond James & Associates sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 13,435 shares — an estimated $632K sold.

Raymond James & Associates first reported a position in SAGE in Q3 2016 and held it in 22 quarters. The position peaked at $6.85M in Q2 2019. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

  • Raymond James & Associates reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 13,435 Sage Therapeutics shares in Q3 2023, an estimated $632K.
  • Raymond James & Associates first reported a position in Sage Therapeutics in Q3 2016 and held it in 22 quarters.
  • Raymond James & Associates's Sage Therapeutics position peaked at $6.85M in Q2 2019.
  • 194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.